Literature DB >> 22800555

Targeted therapies for metastatic melanoma.

Sunandana Chandra1, Anna C Pavlick.   

Abstract

The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22800555     DOI: 10.1016/j.det.2012.05.001

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  3 in total

1.  BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Authors:  Victoria Roulstone; Malin Pedersen; Joan Kyula; David Mansfield; Aadil A Khan; Grainne McEntee; Michelle Wilkinson; Eleni Karapanagiotou; Matt Coffey; Richard Marais; Adel Jebar; Fiona Errington-Mais; Alan Melcher; Richard Vile; Hardev Pandha; Martin McLaughlin; Kevin J Harrington
Journal:  Mol Ther       Date:  2015-01-26       Impact factor: 11.454

2.  Melanoma prevention: are we doing enough? A Canadian perspective.

Authors:  A M Joshua
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

Review 3.  Primary cerebral malignant melanoma: A case report with literature review.

Authors:  Kai Tang; Xiangyi Kong; Gengsheng Mao; Ming Qiu; Haibo Zhu; Lei Zhou; Qingbin Nie; Yi Xu; Shiwei Du
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.